JP Morgan Chase’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.78M | Buy |
489,079
+17,386
| +4% | +$68.5K | ﹤0.01% | 4196 |
|
|
2025
Q4 | $1.67M | Buy |
471,693
+141,096
| +43% | +$573K | ﹤0.01% | 4231 |
|
|
2025
Q3 | $1.32M | Buy |
330,597
+296,350
| +865% | +$934K | ﹤0.01% | 4382 |
|
|
2025
Q2 | $91.8K | Sell |
34,247
-5,472
| -14% | -$11.5K | ﹤0.01% | 5644 |
|
|
2025
Q1 | $56K | Buy |
39,719
+2,698
| +7% | +$4.58K | ﹤0.01% | 5841 |
|
|
2024
Q4 | $73.7K | Sell |
37,021
-41,792
| -53% | -$109K | ﹤0.01% | 5874 |
|
|
2024
Q3 | $248K | Buy |
78,813
+48,976
| +164% | +$154K | ﹤0.01% | 5310 |
|
|
2024
Q2 | $94.3K | Buy |
+29,837
| New | +$119K | ﹤0.01% | 5541 |
|
|
2023
Q3 | – | Sell |
-2,760,081
| Closed | -$5.93M | – | 7427 |
|
|
2023
Q2 | $5.93M | Sell |
2,760,081
-331,733
| -11% | -$746K | ﹤0.01% | 2724 |
|
|
2023
Q1 | $6.03M | Buy |
3,091,814
+87,348
| +3% | +$322K | ﹤0.01% | 2673 |
|
|
2022
Q4 | $11.5M | Sell |
3,004,466
-412,051
| -12% | -$1.65M | ﹤0.01% | 2126 |
|
|
2022
Q3 | $16.5M | Sell |
3,416,517
-37,155
| -1% | -$269K | ﹤0.01% | 1724 |
|
|
2022
Q2 | $27.5M | Buy |
3,453,672
+39,042
| +1% | +$369K | ﹤0.01% | 1380 |
|
|
2022
Q1 | $50.2M | Buy |
3,414,630
+219,788
| +7% | +$3.49M | 0.01% | 1164 |
|
|
2021
Q4 | $64.5M | Sell |
3,194,842
-73,144
| -2% | -$1.76M | 0.01% | 1077 |
|
|
2021
Q3 | $88.8M | Buy |
3,267,986
+69,778
| +2% | +$1.79M | 0.01% | 926 |
|
|
2021
Q2 | $77.9M | Buy |
3,198,208
+55,955
| +2% | +$1.3M | 0.01% | 1008 |
|
|
2021
Q1 | $76.7M | Buy |
3,142,253
+155,335
| +5% | +$4.5M | 0.01% | 969 |
|
|
2020
Q4 | $95.6M | Buy |
2,986,918
+898,606
| +43% | +$29.4M | 0.02% | 789 |
|
|
2020
Q3 | $68.6M | Buy |
2,088,312
+945,539
| +83% | +$40.9M | 0.01% | 836 |
|
|
2020
Q2 | $53.5M | Buy |
+1,142,773
| New | +$43.4M | 0.01% | 861 |
|
Other funds holding ADCT
RG
TCM
PM
EAM
NCM
